



1. NAME OF THE MEDICINAL PRODUCT

DAXITRAN 75mg Hard Capsules
DAXITRAN 110mg Hard Capsules
DAXITRAN 150mg Hard Capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

DAXITRAN 75mg Hard Capsules: Each capsule contains of Dabigatran Etxelilate Mesylate equivalent to 75mg of Dabigatran Etxelilate
DAXITRAN 110mg Hard Capsules: Each capsule contains of Dabigatran Etxelilate Mesylate equivalent to 110mg of Dabigatran Etxelilate
DAXITRAN 150mg Hard Capsules: Each capsule contains of Dabigatran Etxelilate Mesylate equivalent to 150mg of Dabigatran Etxelilate
For the full list of excipients, see section List of excipients.

3. PHARMACEUTICAL FORM

Hard capsule for oral use.
DAXITRAN 75mg Hard Capsules: Size 2, cellulose capsule, white opaque cap imprinted with 'C' and white opaque body imprinted with '77' in black ink containing off-white to yellowish pellets.
DAXITRAN 110mg Hard Capsules: Size 1, cellulose capsule, light blue opaque cap imprinted with 'C' and light blue opaque body imprinted with '72' in black ink containing off-white to yellowish pellets.
DAXITRAN 150mg Hard Capsules: Size 0, cellulose capsule, light blue opaque cap imprinted with 'C' and white opaque body imprinted with '71' in black ink containing off-white to yellowish pellets.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

75mg:

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

110mg:

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

150mg:

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

4.2 Posology and method of administration

Adults:

Primary prevention of Venous Thromboembolism (pVTEp) events in adult patients who have undergone elective knee replacement surgery:

The recommended dose of DAXITRAN is 220mg once daily taken as 2 capsules of 110mg. Treatment should be initiated orally within 1 – 4 hours of completed surgery with a single capsule (110mg) and continuing with 2 capsules once daily thereafter for a total of 10 days.

Primary prevention of Venous Thromboembolism (pVTEp) events in adult patients who have undergone elective hip replacement surgery:

The recommended dose of DAXITRAN is 220mg once daily taken as 2 capsules of 110mg. Treatment should be initiated orally within 1 – 4 hours of completed surgery with a single capsule (110mg) and continuing with 2 capsules once daily thereafter for a total of 10 days.

For both surgeries, if haemostasis is not secured, initiation of treatment should be delayed. If treatment is not started on the day of surgery then treatment should be initiated with 2 capsules once daily.

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF):

The recommended daily dose of DAXITRAN is 300mg taken orally as 150mg hard capsules twice daily. Therapy should be continued life-long.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT, and PE in adults (DVT/PE):

The recommended daily dose of DAXITRAN is 300mg taken as one 150mg capsule twice daily following treatment with a parenteral anticoagulant for at least 5 days. The duration of therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding. Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE.

SPAF, DVT/PE:

For the following groups the recommended daily dose of DAXITRAN is 220mg taken as one 110mg capsule twice daily:

- Patients aged 80 years or above
- Patients who receive concomitant verapamil

For the following groups the daily dose of DAXITRAN of 300mg or 220mg should be selected based on an individual assessment of the thromboembolic risk and the risk of bleeding:

- Patients between 75-80 years
- Patients with moderate renal impairment
- Patients with gastritis, esophagitis or gastroesophageal reflux
- Other patients at increased risk of bleeding

For DVT/PE the recommendation for the use of DAXITRAN 220mg taken as one 110mg capsule twice daily is based on pharmacokinetic and pharmacodynamic analyses and has not been studied in this clinical setting.

In case of intolerance to dabigatran, patients should be instructed to immediately consult their treating physician in order to be switched to alternate acceptable treatment options for prevention of stroke and SEE associated with atrial fibrillation or for DVT/PE.

Special patient populations

Renal impairment:

Renal function should be assessed by calculating the creatinine clearance (CrCl) prior to initiation of treatment with DAXITRAN to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30ml/min). There are no data to support use in patients with severe renal impairment (< 30 mL/min creatinine clearance); treatment in this population with DAXITRAN is not recommended.

While on treatment renal function should be assessed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (such as hypovolemia, dehydration, and with certain comedications, etc).

Dabigatran can be dialysed; there is limited clinical experience to demonstrate the utility of this approach in clinical studies.

Primary prevention of venous thromboembolism events in adult patients who have undergone elective hip replacement surgery or total knee replacement surgery (pVTEp):

In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), there is limited clinical experience. These patients should be treated with caution. The recommended dose is 150mg taken once daily as 2 capsules of 75mg.

Treatment with DAXITRAN should be initiated orally within 1 - 4 hours of completed surgery with a single capsule of 75mg and continuing with 2 capsules of 75mg once daily thereafter for a total of 10 days (following knee replacement surgery) or 28-35 days (following hip replacement surgery).

For both surgeries, if haemostasis is not secured, initiation of treatment should be delayed. If treatment is not started on the day of surgery then treatment should be initiated with 2 capsules once daily.

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF):

In patients with moderate renal impairment (CrCl 30-50mL/min) the renal function should be assessed at least once a year.

No dose adjustment necessary, patients should be treated with a daily dose of 300mg taken orally as 150mg hard capsules twice daily.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT, and PE in adults (DVT/PE):

Treatment with DAXITRAN in patients with severe renal impairment (CrCL < 30 mL/min) is contraindicated. No dose adjustment is necessary in patients with mild renal impairment (CrCL 50 - ≤ 80 mL/min). For patients with moderate renal impairment (CrCL 30-50 mL/min) the recommended dose of DAXITRAN is also 300mg taken as one 150mg capsule twice daily. However, for patients with high risk of bleeding, a dose reduction of DAXITRAN to 220mg taken as one 110mg capsule twice daily should be considered. Close clinical surveillance is recommended in patients with renal impairment.

Elderly:

Pharmacokinetic studies in older subjects demonstrate an increase in drug exposure in those patients with age-related decline of renal function.

See also dose and administration in renal impairment.

Primary prevention of venous thromboembolism events in adult patients who have undergone elective hip replacement surgery or total knee replacement surgery (pVTEp):

As renal impairment may be frequent in the elderly (>75 years), renal function should be assessed by calculating the creatinine clearance (CrCl) prior to initiation of treatment with DAXITRAN to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30mL/min). The renal function should also be assessed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (such as hypovolemia, dehydration, and with certain comedications, etc).

In elderly patients (> 75 years) there is limited clinical experience. These patients should be treated with caution. The recommended dose is 150mg taken once daily as 2 capsules of 75mg.

After knee replacement surgery treatment should be initiated orally within 1 – 4 hours of completed surgery with a single capsule and continuing with 2 capsules once daily thereafter for a total of 10 days.

After hip replacement surgery treatment should be initiated orally within 1 – 4 hours of completed surgery with a single capsule and continuing with 2 capsules once daily thereafter for a total of 28-35 days.

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF):

As renal impairment may be frequent in the elderly (>75 years), renal function should be assessed by calculating the creatinine clearance (CrCl) prior to initiation of treatment with DAXITRAN to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30mL/min). The renal function should also be assessed at least once a year in patients treated with DAXITRAN or more frequently as needed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (such as hypovolemia, dehydration, and with certain comedications, etc).

As renal impairment may be frequent in the elderly (>75 years), renal function should be assessed by calculating the CrCL prior to initiation of treatment with DAXITRAN to exclude patients with severe renal impairment (i.e. CrCL < 30 mL/min). The renal function should also be assessed at least once a year in patients treated with DAXITRAN or more frequently as needed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (such as hypovolemia, dehydration, and with certain comedications, etc).

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT, and PE in adults (DVT/PE):

Patients between 75-80 years should be treated with a daily dose of 300mg taken as one 150mg capsule twice daily. A dose of 220mg taken as one 110mg capsule twice daily can be individually considered, at the discretion of the physician, when the thromboembolic risk is low and the bleeding risk is high.

Patients aged 80 years or above should be treated with a daily dose of 220mg taken as one 110mg capsule twice daily due to the increased risk of bleeding in this population.

As renal impairment may be frequent in the elderly (>75 years), renal function should be assessed by calculating the CrCL prior to initiation of treatment with DAXITRAN to exclude patients with severe renal impairment (i.e. CrCL < 30 mL/min). The renal function should also be assessed at least once a year in patients treated with DAXITRAN or more frequently as needed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (such as hypovolemia, dehydration, and with certain comedications, etc).

Weight:

Given the available clinical and kinetic data, no adjustment is necessary, but close clinical surveillance is recommended in patients with a body weight < 50 kg.

Gender:

Given the available clinical and kinetic data, no dose adjustment is necessary.

Concomitant use of DAXITRAN with strong P-glycoprotein inhibitors, e.g. amiodarone, quinidine or verapamil:

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery (pVTEp):

Dosing should be reduced to DAXITRAN 150mg taken once daily as 2 capsules of 75mg in patients who concomitantly receive DAXITRAN and amiodarone, quinidine or verapamil.

Treatment initiation with verapamil should be avoided in patients who have undergone elective total hip replacement surgery or total knee replacement surgery who are already treated with DAXITRAN. Simultaneous initiation of treatment with DAXITRAN and verapamil should also be avoided.

Treatment with DAXITRAN should be initiated orally within 1 - 4 hours of completed surgery with a single capsule of 75mg and continuing with 2 capsules of 75mg once daily thereafter for a total of 10 days (following knee replacement surgery) or 28-35 days (following hip replacement surgery). For both surgeries, if haemostasis is not secured, initiation of treatment should be delayed. If treatment is not started on the day of surgery then treatment should be initiated with 2 capsules once daily.

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF):

No dose adjustment is necessary for concomitant use of amiodarone or quinidine.

Dosing should be reduced to 220mg taken as one 110mg capsule twice daily in patients who receive concomitantly dabigatran etexilate and verapamil. In this situation DAXITRAN and verapamil should be taken at the same time.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT, and PE in adults (DVT/PE):

No dose adjustment is necessary for concomitant use of amiodarone or quinidine.

Dosing should be reduced to 220mg taken as one 110mg capsule twice daily in patients who receive concomitantly dabigatran etexilate and verapamil. In this situation DAXITRAN and verapamil should be taken at the same time.

Patients at risk of bleeding:

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF):

The presence of the following factors may increase the risk of bleeding: e.g. age ≥ 75 years, moderate renal impairment (30-50 mL CrCL/min), concomitant treatment with strong P-gp inhibitors, antiplatelets or previous gastro-intestinal bleed. For patients with one or more than one of these risk factors, a reduced daily dose of 220mg given as 110mg twice daily may be considered at the discretion of the physician.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT, and PE in adults (DVT/PE):

Patients with an increased bleeding risk should be closely monitored clinically (looking for signs of bleeding or anaemia). Dose adjustment should be decided at the discretion of the physician, following assessment of the potential benefit and risk to an individual patient. A coagulation test may help to identify patients with an increased bleeding risk caused by excessive dabigatran exposure. When excessive dabigatran exposure is identified in patients at high risk of bleeding, a reduced dose of 220mg taken as one 110mg capsule twice daily is recommended. When clinically relevant bleeding occurs, treatment should be interrupted.

For subjects with gastritis, esophagitis, or gastroesophageal reflux, the dose of 220mg taken as one 110mg capsule twice daily may be considered due to the elevated risk of major gastro-intestinal bleeding.

Hepatic impairment:

Patients with elevated liver enzymes > 2 upper limit of normal (ULN) were excluded in the main trials. No treatment experience is available for this subpopulation of patients, and therefore the use of DAXITRAN is not recommended in this population. Hepatic impairment or liver disease expected to have any impact on survival is contraindicated.

Post-surgical patients with an increased risk for bleeding:

DAXITRAN should be resumed/ started after an invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established.

Patients at risk for bleeding or patients at risk of overexposure, notably patients with moderate renal impairment (creatinine clearance 30 – 50 mL/min), should be treated with caution.

Paediatric population:

pVTEp and SPAF:

DAXITRAN has not been investigated in patients <18 years of age in the indication of:

- Primary prevention of venous thromboembolic events in patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
- Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
- Treatment of paediatric patients with DAXITRAN is therefore not recommended.

DVT/PE:

The safety and efficacy of DAXITRAN have not been established in paediatric patients <18 years of age. Therefore, DAXITRAN is not indicated in this patient population.

Switching from DAXITRAN treatment to parenteral anticoagulant:

pVTEp:

It is recommended to wait 24 hours after the last dose before switching from DAXITRAN to a parenteral anticoagulant.

SPAF and DVT/PE:

It is recommended to wait 12 hours after the last dose before switching from DAXITRAN to a parenteral anticoagulant.

Switching from parenteral anticoagulants treatment to DAXITRAN:

DAXITRAN should be given 0-2 hours prior to the time that the next dose of the alternate therapy would be due, or at the time of discontinuation in case of continuous treatment (e.g. intravenous UFH).

Switching from Vit. K antagonists to DAXITRAN:

SPAF and DVT/PE:

The Vit. K antagonist should be stopped. DAXITRAN can be given as soon as the INR is < 2.0.

Switching from DAXITRAN to Vit. K antagonists (VKA):

SPAF and DVT/PE:

The starting time of the VKA should be adjusted according to the patient's CrCL as follows:

- CrCL ≥ 50 mL/min, start VKA 3 days before discontinuing dabigatran etexilate.
 - CrCL ≥ 30-< 50 mL/min, start VKA 2 days before discontinuing dabigatran etexilate.
- Because DAXITRAN can impact the International Normalized Ratio (INR), the INR will better reflect VKA's effect only after DAXITRAN has been stopped for at least 2 days. Until then, INR values should be interpreted with caution.

Cardioversion:

SPAF and DVT/PE:

Patients can stay on DAXITRAN while being cardioverted.

Catheter ablation for atrial fibrillation:

SPAF:

Catheter ablation can be conducted in patients on 150mg twice daily DAXITRAN treatment. DAXITRAN treatment does not need to be interrupted.

Percutaneous coronary intervention (PCI) with stenting:

SPAF:

Patients with non-valvular atrial fibrillation who undergo a PCI with stenting can be treated with DAXITRAN in combination with antiplatelets after haemostasis is achieved.

Missed dose

pVTEp:

Continue with your remaining daily doses of DAXITRAN at the same time of the next day. Do not take a double dose to make up for missed individual doses.

SPAF and DVT/PE:

A forgotten DAXITRAN dose may still be taken up to 6 hours prior to the next scheduled dose. From 6 hours prior to the next scheduled dose on, the missed dose should be omitted.

Do not take a double dose to make up for missed individual doses.

Method of administration

DAXITRAN can be taken with or without food. DAXITRAN should be swallowed as a whole with a glass of water, to facilitate delivery to the stomach.

Patients should be instructed not to open the capsule as this may increase the risk of bleeding.

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients
- Patients with severe renal impairment (CrCl < 30 mL/min)
- Active clinically significant bleeding
- Lesion or condition, if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
- Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc), oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances. These are switching anticoagulant therapy, when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation
- Hepatic impairment or liver disease expected to have any impact on survival
- Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole, cyclosporine, itraconazole and dronedarone
- Prosthetic heart valves requiring anticoagulant treatment.

4.4 Special warnings and precautions for use

Haemorrhagic risk:

As with all anticoagulants, Dabigatran etexilate should be used with caution in conditions with an increased risk of bleeding. Bleeding can occur at any site during therapy with dabigatran etexilate. An unexplained fall in hemoglobin and/or hematocrit or blood pressure should lead to a search for a bleeding site.

For situation of life-threatening or uncontrolled bleeding, when rapid reversal of the anticoagulation effects of dabigatran etexilate is required, the specific reversal agent (idarucizumab) is available.

dabigatran etexilate treatment does not require anticoagulant monitoring. The INR test is unreliable in patients on dabigatran etexilate and false positive INR elevations have been reported. Therefore INR tests should not be performed.

Tests of anticoagulant activity such as thrombin time (TT), ecarin clotting time (ECT) and activated partial thromboplastin time (aPTT) are available to detect excessive dabigatran etexilate activity.

Dabigatran etexilate related anticoagulant can be assessed by ECT or TT. If ECT or TT is not available, the aPTT test provides an approximation of dabigatran etexilate anticoagulant activity.

For SPAF: In atrial fibrillation patients in RE-LY treated with 150mg bid an aPTT of greater than 2.0 – 3.0 fold of normal range at trough was associated with an increased risk of bleeding.

Pharmacokinetic studies demonstrated an increase in drug exposure in patients with reduced renal function including age-related decline of renal function. Dabigatran etexilate is contraindicated in cases of severe renal impairment (CrCL < 30 mL/min).

Patients who develop acute renal failure should discontinue dabigatran etexilate.

Factors, such as decreased renal function (30 - 50mL/min CrCL), age > 75 years, or strong P-gp-inhibitor comedication are associated with increased dabigatran etexilate plasma levels. The presence of one or more than one of these factors may increase the risk of bleeding.

The concomitant use of dabigatran etexilate with the following treatments has not been studied and may increase the risk of bleeding: unfractionated heparins (except at doses necessary to maintain patency of central venous or arterial catheter or during catheter ablation for atrial fibrillation) and heparin derivatives, low molecular weight heparins (LMWH), fondaparinux, desirudin, thrombolytic agents, GPIIb/IIIa receptor antagonists, ticlopidine, dextran, sulfapyrazone, rivaroxaban, prasugrel, vitamin K antagonists, and P-gp inhibitors such as but not limited to itraconazole, tacrolimus, cyclosporine, ritonavir, tipranavir, nelfinavir and saquinavir. The concomitant use of dabigatran etexilate with the fixed-dose combination of the P-gp inhibitors glecaprevir/pibrentasvir has been shown to increase exposure of dabigatran etexilate and may increase the risk of bleeding.

The concomitant use of dronedarone increases exposure of dabigatran etexilate and is not recommended.

The concomitant use of ticagrelor increases the exposure to dabigatran etexilate and may show pharmacodynamic interaction, which may result in an increased risk of bleeding.

Bleeding risk may be increased in patients concomitantly treated with selective serotonin re-uptake inhibitors (SSRI) or selective serotonin norepinephrine re-uptake inhibitors (SNRI).

Use of fibrinolytic agents for the treatment of acute ischemic stroke:

The use of fibrinolytic agents for the treatment of acute ischemic stroke may be considered if the patient presents with a thrombin time (TT), or Ecarin clotting time (ECT), or activated partial thromboplastin time (aPTT) not exceeding the upper limit of normal (ULN) according to the local reference range.

In situations where there is an increased haemorrhagic risk (e.g. recent biopsy or major trauma, bacterial endocarditis) close observation (looking for signs of bleeding or anaemia) is generally required.

For pVTEp: NSAIDs given for short-term perioperative analgesia have been shown not to be associated with increased bleeding risk when given in conjunction with dabigatran etexilate. There is limited evidence regarding the use of regular NSAID medication with half-lives of less than 12 hours during treatment with dabigatran etexilate and this has not suggested additional bleeding risk.

For SPAF: Co-administration of antiplatelet (including ASA and clopidogrel) and NSAID therapies increase the risk of bleeding. Specifically, with concomitant intake of antiplatelets or strong P-gp inhibitors in patients aged ≥ 75 years, the risk of major bleeding, including gastrointestinal bleeding, increases. If bleeding is clinically suspected, appropriate measures such as testing for occult blood in stool, or testing for a drop in hemoglobin is suggested.

Interaction with P-gp inducers:

The concomitant use of dabigatran etexilate with the strong P-gp inducer rifampicin reduces dabigatran etexilate plasma concentrations. Other P-gp inducers such as St. John's Wort or carbamazepine are also expected to reduce dabigatran etexilate plasma concentrations and should be co-administered with caution.

Patients with antiphospholipid syndrome:

Patients with antiphospholipid syndrome (especially if triple-positive for antiphospholipid antibodies) are at an increased risk for thromboembolic events.

While the efficacy of dabigatran etexilate is established for the treatment and prevention of venous thromboembolism it has not been studied specifically in the subpopulation of patients with antiphospholipid syndrome.

Therefore, careful consideration of all treatment options (including standard treatment such as vitamin K antagonists) is recommended before use of dabigatran etexilate in patients with antiphospholipid syndrome.

Surgery and Interventions:

Patients on dabigatran etexilate who undergo surgery or invasive procedures are at increased risk for bleeding. Therefore surgical interventions may require the temporary discontinuation of dabigatran etexilate.

In case of emergency surgery or urgent procedures when rapid reversal of the anticoagulation effect is required the specific reversal agent, idarucizumab to dabigatran etexilate is available.

Reversing dabigatran etexilate therapy exposes patients to the thrombotic risk of their underlying disease. Dabigatran etexilate treatment can be re-initiated 24 hours after administration of idarucizumab, if the patient is clinically stable and adequate hemostasis has been achieved.

For SPAF: Patients can stay on dabigatran etexilate while being cardioverted. Dabigatran etexilate treatment (150mg twice daily) does not need to be interrupted in patients undergoing catheter ablation for atrial fibrillation.

Preoperative Phase:

Due to an increased risk of bleeding dabigatran etexilate may be stopped temporarily in advance of invasive or surgical procedures.

Emergency Surgery or Urgent Procedure:

The specific reversal agent (idarucizumab) of dabigatran etexilate is available for the rapid reversal of the anticoagulation effect.

Acute Surgery/Intervention:

</

Dronedaronе: dabigatran exposure was increased by 2.1 fold (+114%) after single or 2.4 fold (+136%) after multiple doses of dronedarone, respectively.

Ticagrelor: Dabigatran exposure in healthy subjects was increased by 1.46 fold (+ 46%) in the presence of ticagrelor at steady state or by 1.73 fold (+73%) when a loading dose of ticagrelor was administered simultaneously with a single dose of 75mg dabigatran etexilate.

Dabigatran steady state exposure in healthy subjects was increased by 1.26 fold (+ 26 %) in the presence of ticagrelor at steady state or by 1.49 fold (+49%) when a loading dose of ticagrelor was administered simultaneously with 110mg dabigatran etexilate. The increase in exposure was less pronounced when the 180mg ticagrelor loading dose was given two hours after dabigatran intake (+27%).

P- glycoprotein substrate:

Digoxin: In a study performed with 24 healthy subjects, when dabigatran was coadministered with digoxin, no changes on digoxin and no clinical relevant changes on dabigatran exposure have been observed.

P-glycoprotein inducers:

After 7 days of treatment with 600mg rifampicin qd total dabigatran AUC0-∞ and C_{max} were reduced by 67% and 66% compared to the reference treatment, respectively.

The concomitant use with P-gp inducers (e.g., rifampicin) reduces exposure to dabigatran and should be avoided.

4.6 Fertility, pregnancy and lactation

Pregnancy

No clinical data on exposed pregnancies are available. The potential risk for humans is unknown.

Women of child-bearing potential should avoid pregnancy during treatment with dabigatran etexilate and when pregnant, women should not be treated with dabigatran etexilate unless the expected benefit is greater than the risk.

Lactation

No clinical data are available. As a precaution, breast-feeding should be stopped.

Fertility

No clinical data available. Non-clinical reproductive studies did not show any adverse effects on fertility or postnatal development of the neonate.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8 Undesirable effects

Adverse reactions are generally associated to the pharmacological mode of action of dabigatran etexilate and represent bleeding associated events that may occur in different anatomical regions and organs.

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery (pVTEp):

In patients treated for VTE prevention after hip or knee replacement surgery the observed incidences of adverse reactions of dabigatran etexilate were in the range of enoxaparin.

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF):

The observed incidences of adverse reactions of dabigatran etexilate in patients treated for stroke prevention in patients with atrial fibrillation were in the range of warfarin except gastrointestinal disorders which appeared at a higher rate in the dabigatran etexilate arms.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults (DVT/PE):

The overall frequency of adverse reactions in patients receiving dabigatran etexilate for acute DVT/PE treatment was lower for dabigatran etexilate compared to warfarin.

Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults (PVT/PE):

The overall frequency of adverse reactions in patients treated for recurrent DVT/PE prevention was lower for dabigatran etexilate compared to warfarin.

Adverse reactions identified from studies and post-marketing data in:

- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery (pVTEp)
- Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF)
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults

Blood and lymphatic system disorders

Anemia, thrombocytopenia, neutropenia*, agranulocytosis*

Immune system disorders

Drug hypersensitivity including pruritus, rash and urticaria, bronchospasm*, angioedema*, anaphylactic reaction*.

Nervous system disorders

Intracranial haemorrhage

Vascular disorders

Haematoma, haemorrhage

Respiratory, thoracic and mediastinal disorders

Epistaxis, haemoptysis

Gastrointestinal disorders

Gastrointestinal haemorrhage, abdominal pain, diarrhoea, dyspepsia, nausea, gastrointestinal ulcer, including oesophageal ulcer, gastroesophagitis, gastroesophageal reflux disease, vomiting, dysphagia

Hepatobiliary disorders

Hepatic function abnormal

Skin and subcutaneous tissue disorders

Skin haemorrhage, alopecia*

Musculoskeletal, connective tissue and bone disorders

Haemarthrosis

Renal and urinary disorders

Urinary tract haemorrhage

General disorders and administration site conditions

Injection site haemorrhage, catheter site haemorrhage

Injury, poisoning and procedural complications

Traumatic haemorrhage, incision site haemorrhage

* including post-marketing data

Additional specific adverse reactions identified per indication

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery (pVTEp):

Vascular disorders

Wound haemorrhage

General disorders and administration site conditions

Bloody discharge

Injury, poisoning and procedural complications

Post-procedural haematoma, post-procedural haemorrhage, anaemia post-operative, post-procedural discharge, wound secretion

Surgical and medical procedures

Wound drainage, post-procedural drainage

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF):

None

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT, and PE in adults (DVT/PE):

None

4.9 Overdose

Symptoms

Overdose following administration of dabigatran etexilate may lead to haemorrhagic complications due to its pharmacodynamic properties. Doses of dabigatran etexilate beyond those recommended expose the patient to increased risk of bleeding.

Therapy

In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. Since dabigatran etexilate is excreted predominantly by the renal route adequate diuresis must be maintained.

Depending on the clinical situation appropriate standard treatment, e.g. surgical haemostasis as indicated and blood volume replacement, should be undertaken.

For situations when rapid reversal is required the specific reversal agent (idarucizumab) antagonising the

pharmacodynamics effect of dabigatran etexilate is available.

In addition, consideration may be given to the use of fresh whole blood or fresh frozen plasma.

Coagulation factor concentrations (activated or non-activated) or recombinant Factor VIIa may be taken into account. There is some experimental evidence to support the role of these agents in reversing the anticoagulant effect of dabigatran etexilate but their usefulness in clinical settings has not yet been systematically demonstrated. Consideration should also be given to administration of platelet concentrates in cases where thrombocytopenia is present or long acting antiplatelet drugs have been used. All symptomatic treatment has to be given according to the physician's judgement.

As protein binding is low, dabigatran etexilate is dialysable, however there is limited clinical experience in using dialysis in this setting.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapy group: Direct thrombin inhibitor; ATC Code: B01AE07 - dabigatran etexilate

Mode of Action

Dabigatran etexilate is a small molecule prodrug which does not exhibit any pharmacological activity. After oral administration, dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalysed hydrolysis in plasma and in the liver. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma.

Pharmacodynamics

Since thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of thrombus. Dabigatran also inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.

In-vivo and *ex-vivo* animal studies have demonstrated antithrombotic efficacy and anticoagulant activity of dabigatran after intravenous administration and of dabigatran etexilate after oral administration in various animal models of thrombosis.

There is a close correlation between plasma Dabigatran concentrations and degree of anticoagulant effect. dabigatran prolongs the aPTT, ECT and TT.

5.2 Pharmacokinetic properties

Absorption

After oral administration of dabigatran Etexilate in healthy volunteers, the pharmacokinetic profile of dabigatran in plasma is characterized by a rapid increase in plasma concentrations with peak concentration (C_{max}) attained within 0.5 and 2.0 hours post administration. C_{max} and the area under the plasma concentration-time curve (AUC) were dose proportional.

The absolute bioavailability of dabigatran following oral administration of dabigatran etexilate as HPMC capsule was approximately 6.5 %.

Food does not affect the bioavailability of dabigatran etexilate but delays the time to peak plasma concentrations by 2 hours.

The oral bioavailability may be increased by about 1. 4 fold (+37%) compared to the reference capsule formulation when the pellets are taken without the HPMC capsule shell. Hence, the integrity of the HPMC capsules should always be preserved in clinical use to avoid unintentionally increased bioavailability of dabigatran etexilate. Therefore, patients should be advised not to open the capsules and taking the pellets alone (e.g. sprinkled over food or into beverages).

Distribution

Low (34-35%) concentration independent binding of dabigatran to human plasma proteins was observed. The volume of distribution of dabigatran of 60 – 70 L exceeded the volume of total body water indicating moderate tissue distribution of dabigatran.

Biotransformation

After oral administration, dabigatran etexilate is rapidly and completely converted to dabigatran, which is the active form in plasma. The cleavage of the prodrug dabigatran etexilate by esterase-catalysed hydrolysis to the active principle dabigatran is the predominant metabolic reaction. Dabigatran is subject to conjugation forming pharmacologically active acylglucuronides. Four positional isomers, 1-O, 2-O, 3-O, 4-O-acylglucuronide exist, each accounts for less than 10% of total dabigatran in plasma. Traces of other metabolites were only detectable with highly sensitive analytical methods. Dabigatran is eliminated primarily in the unchanged form in the urine, at a rate of approximately 100 ml/min corresponding to the glomerular filtration rate.

Elimination

After C_{max}, plasma concentrations of dabigatran showed a biexponential decline with a mean terminal half-life of approximately 11 hours in healthy elderly subjects. After multiple doses a terminal half-life of about 12-14 hours was observed. The half-life was independent of dose. However, half-life is prolonged if renal function is impaired as shown below, in Table 2.

Metabolism and excretion of dabigatran were studied following a single intravenous dose of radiolabeled dabigatran. After an intravenous dose, the dabigatran-derived radioactivity was eliminated primarily in the urine (85%). Faecal excretion accounted for 6% of the administered dose. Recovery of the total radioactivity ranged from 88 - 94% of the administered dose by 168 hours post dose.

Table 2: Half-life of total dabigatran in healthy subjects and subjects with impaired renal function

glomerular filtration rate (CrCl)	gMean (gCV%; range) half-life
[mL/min]	[h]
> 80	13.4 (25.7%; 11.0-21.6)
> 50 - ≤ 80	15.3 (42.7%; 11.7-34.1)
> 30 - ≤ 50	18.4 (18.5%; 13.3-23.0)
≤ 30	27.2 (15.3%; 21.6-35.0)

Special Populations

Renal impairment

The exposure (AUC) of dabigatran after the oral administration of dabigatran etexilate in a study was approximately 3-fold higher in volunteers with moderate renal insufficiency (CrCl between 30 - 50ml/min) than in those without renal insufficiency.

In a small number of volunteers with severe renal insufficiency (CrCl 10 - 30 ml/min), the exposure (AUC) to dabigatran was approximately 6 times higher and the half-life approximately 2 times longer than that observed in a population without renal insufficiency

Clearance of dabigatran by hemodialysis was investigated in patients with end-stage renal disease (ESRD) without atrial fibrillation. Dialysis was conducted with 700ml/min dialysate flow rate, four hour duration, a blood flow rate of either 200 ml/min or 350 - 390 ml/min. This resulted in a removal of 50% or 60% of free or total dabigatran concentrations, respectively. The amount of drug cleared by dialysis is proportional to the blood flow rate. The anticoagulant activity of dabigatran decreased with decreasing plasma concentrations and the PK/PD relationship was not affected by the procedure.

Elderly

Specific pharmacokinetic studies with elderly subjects showed an increase of 1.4- to 1.6-fold (+40 to 60%) in the AUC and of more than 1.25-fold (+25 %) in C_{max} compared to young subjects.

The AUC_{0-ss} and C_{max,ss} in male and female elderly subjects (> 65 y) were approximately 1.9 fold and 1.6-fold higher for elderly females compared to young females and 2.2 and 2.0 fold higher for elderly males than in male subjects of 18 - 40 years of age.

The observed increase of dabigatran exposure correlated with the age-related reduction in creatinine clearance.

Hepatic insufficiency:

No change in dabigatran exposure was seen in a study with moderate hepatic insufficiency (Child Pugh B).

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery (pVTEp):

Patients with moderate and severe hepatic impairment (Child-Pugh classification B and C) or liver disease expected to have any impact on survival or with elevated liver enzymes ≥ 2 Upper Limit Normal (ULN) were excluded in clinical trials.

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF):

Patients with active liver disease including but not limited to the persistent elevation of liver enzymes ≥ 2 Upper Limit Normal (ULN), or hepatitis A, B or C were excluded in clinical trials.

Treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults (DVT/PE):

Patients with moderate and severe hepatic impairment (Child-Pugh classification B and C) or liver disease expected to have any impact on survival or with elevated liver enzymes ≥ 2 Upper Limit Normal (ULN) were excluded in clinical trials.

Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults (DVT/PE):

Patients with moderate and severe hepatic impairment (Child-Pugh classification B and C) or liver disease expected to have any impact on survival or with elevated liver enzymes ≥ 2 Upper Limit Normal (ULN) were excluded in clinical trials.

Body weight:

The dabigatran trough concentrations were about 20% lower in patients with a BW > 100 kg compared with 50 - 100 kg. The majority (80.8%) of the subjects were in the ≥ 50 kg and < 100 kg category with no clear difference detected. Limited data in patients ≤ 50 kg are available.

Gender:

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery (pVTEp):

Drug exposure in the primary VTE prevention studies was about 1.4- to 1.5-fold (+ 40 % to 50 %) higher in female patients. This finding had no clinical relevance.

Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF):

In atrial fibrillation patients females had on average 1.3-fold (+30 %) higher trough and post-dose concentrations. This finding had no clinical relevance.

Ethnic origin:

The pharmacokinetics of dabigatran was investigated in Caucasian and Japanese volunteers after single and multiple doses. Ethnic origin does not affect the pharmacokinetics of dabigatran in a clinically relevant manner. Limited pharmacokinetic data in black patients are available which suggest no relevant differences.

Drug-drug interactions

In vitro interaction studies did not show any inhibition or induction of cytochrome P450. This has been confirmed by *in vivo* studies in healthy volunteers, who did not show any interaction between dabigatran etexilate treatment and the following drugs: atorvastatin (CYP3A4), and diclofenac (CYP2C9).

Atorvastatin: When dabigatran etexilate was coadministered with atorvastatin, a CYP3A4 substrate, exposure of atorvastatin, atorvastatin metabolites and of dabigatran were unchanged indicating a lack of interaction.

Diclofenac: When dabigatran etexilate was coadministered with diclofenac, a CYP2C9 substrate, pharmacokinetics of both drugs remained unchanged indicating a lack of interaction between dabigatran etexilate and diclofenac.

P-gp inhibitor / inducer interactions:

The pro-drug dabigatran etexilate but not dabigatran is a substrate of the efflux transporter P-glycoprotein (P-gp). Therefore co-medications with P-gp transporter inhibitors and inducers have been investigated.

Co-medication with P-gp inhibitors:

Amiodarone: When dabigatran etexilate was coadministered with a single oral dose of 600 mg amiodarone, the extent and rate of absorption of amiodarone and its active metabolite DEA were essentially unchanged. The dabigatran AUC and Cmax were increased by about 1.6-fold and 1.5-fold (+60 % and 50 %), respectively. **For SPAF:** In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received amiodarone (see "Drug interactions").

Dronedaronе: When dabigatran etexilate and dronedarone were given at the same time total dabigatran AUC0-∞ and C_{max} values increased by about 2.4-fold and 2.3-fold (+136 % and 125%), respectively, after multiple dosing of 400 mg dronedarone bid, and about 2.1-fold and 1.9-fold (+114% and 87%), respectively, after a single dose of 400 mg. The terminal half-life and renal clearance of dabigatran were not affected by dronedarone. When single and multiple doses of dronedarone were given 2 h after dabigatran etexilate, the increases in dabigatran AUC0-∞ were 1.3-fold and 1.6 fold, respectively.

Verapamil: When dabigatran etexilate was coadministered with oral verapamil, the C_{max} and AUC of dabigatran were increased depending on timing of administration and formulation of verapamil.

The greatest elevation of dabigatran exposure was observed with the first dose of an immediate release formulation of verapamil administered one hour prior to dabigatran etexilate intake (increase of C_{max} by about 2.8-fold (+180%) and AUC by about 2.5-fold (+150%). The effect was progressively decreased with administration of an extended release formulation (increase of C_{max} by about 1.9-fold (+90%) and AUC by about 1.7-fold (+70%) or administration of multiple doses of verapamil (increase of C_{max} by about 1.6-fold (+60%) and AUC by about 1.5-fold (+50%). This can be explained by the induction of P-gp in the gut by chronic verapamil treatment.

There was no meaningful interaction observed when verapamil was given 2 hours after dabigatran etexilate (increase of C_{max} by about 10% and AUC by about 20%). This is explained by completed dabigatran absorption within 2 hours.

No data are available for the parenteral application of verapamil; based on the mechanism of the interaction, no meaningful interaction is expected.

For SPAF: In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received verapamil.

Ketoconazole: Systemic ketoconazole increased total dabigatran AUC0-∞ and C_{max} values by about 2.4-fold (+138 % and 135%), respectively, after a single dose of 400 mg , and about 2.5-fold (+153% and 149%), respectively, after multiple dosing of 400 mg ketoconazole qd. The time to peak, terminal half-life and mean residence time were not affected by ketoconazole.

Clarithromycin: When clarithromycin 500 mg twice daily was administered together with dabigatran etexilate no clinically relevant PK-interaction was observed (increased of C_{max} by about 15 % and AUC by about 19%).

Quinidine: Quinidine was given as 200 mg dose every 2nd hour up to a total dose of 1000 mg. dabigatran etexilate was given bid over 3 consecutive days, on the 3rd day either with or without quinidine. dabigatran AUC_{0-ss} and C_{max,ss} were increased on average by about 1.5-fold (+53 % and 56 %), respectively with concomitant quinidine.

Ticagrelor: When a single dose of 75mg dabigatran etexilate was coadministered simultaneously with a loading dose of 180 mg ticagrelor, the dabigatran AUC and C_{max} were increased by 1.73-fold and 1.95-fold (+73% and 95%), respectively. After multiple doses of ticagrelor 90 mg b.i.d. the increase of dabigatran exposure is reduced to 1.56-fold and 1.46-fold (+57% and 46%) for C_{max} and AUC, respectively.

Concomitant administration of a loading dose of 180 mg ticagrelor and 110 mg dabigatran etexilate (in steady state) increased the dabigatran AUC_{0-ss} and by C_{max,ss} by 1.49-fold and 1.65-fold (+49% and 65%), respectively, compared with dabigatran etexilate given alone. When a loading dose of 180 mg ticagrelor was given 2 hours after 110 mg dabigatran etexilate (in steady state), the increase of dabigatran AUC_{0-ss} and C_{max,ss} was reduced to 1.27-fold and 1.23-fold (+27% and 23%), respectively, compared with dabigatran etexilate given alone. Concomitant administration of 90 mg ticagrelor BID (maintenance dose) with 110 mg dabigatran etexilate increased the adjusted dabigatran AUC_{0-ss} and C_{max,ss} 1.26-fold and 1.29-fold, respectively, compared with dabigatran etexilate given alone.

Co-medication with P-gp substrates:

Digoxin: When dabigatran etexilate was coadministered with digoxin, a P-gp substrate, no PK-interaction was observed. Neither dabigatran nor the pro-drug dabigatran etexilate is a clinically relevant P-gp inhibitor.

Co-medication with P-gp inducers:

Rifampicine: Pre-dosing of the probe inducer rifampicin at a dose of 600 mg qd for 7 days decreased total dabigatran peak and total exposure by 65.5 and 67 %, respectively. The inducing effect was diminished resulting in dabigatran exposure close to the reference by day 7 after cessation of rifampicin treatment. No further increase in bioavailability was observed after another 7 days.

Co-medications with platelet-inhibitors:

Acetylsalicylic acid (ASA): The effect of concomitant administration of dabigatran etexilate and acetylsalicylic acid (ASA) on the risk of bleeds was studied in patients with atrial fibrillation in a phase II study in which a randomized ASA coadministration was applied. Based on logistic regression analysis, co-administration of ASA and 150 mg dabigatran etexilate twice daily may increase the risk for any bleeding from 12 % to 18 % and 24% with 81 mg and 325 mg ASA, respectively.

From the data gathered in the phase III study RE-LY it was observed that ASA or clopidogrel co-medication with dabigatran etexilate at dosages of 110 or 150 mg bid may increase the risk of major bleeding. The higher rate of bleeding events by ASA or clopidogrel co-medication was, however, also observed for warfarin.

NSAIDs: NSAIDs given for short-term perioperative analgesia have been shown not to be associated with increased bleeding risk when given in conjunction with dabigatran etexilate. There is limited evidence regarding the use of regular NSAID medication with half-lives of less than 12 hours during treatment with dabigatran etexilate and this has not suggested additional bleeding risk.

For SPAF: NSAIDs increased the risk of bleeding in RE-LY in all treatment groups.

Clopidogrel: In a phase I study in young healthy male volunteers, the concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times (CBT) compared to clopidogrel monotherapy. In addition, dabigatran AUC_{0-ss} and C_{max,ss} and the coagulation measures for dabigatran effect, aPTT, ECT or TT (anti FIIa), or the inhibition of platelet aggregation (IPA) as measure of clopidogrel effect remained essentially unchanged comparing combined treatment and the respective mono-treatments. With a

loading dose of 300 or 600 mg clopidogrel, dabigatran AUC_{0-ss} and C_{max,ss} were increased by about 1.3- to 1.4-fold (+30 to 40%).

Antiplatelets or other anticoagulants: The concomitant use of dabigatran etexilate and antiplatelets or other anticoagulants may increase the risk of bleeding.

Co-medication with selective serotonin re-uptake inhibitors:

SSRIs increased the risk of bleeding in RE-LY in all treatment groups.

Co-medication with gastric pH-elevating agents:

The changes in dabigatran exposure determined by population pharmacokinetic analysis caused by PPIs and antacids were not considered clinically relevant because the magnitude of the effect were minor (fractional decrease in bioavailability not significant for antacids and 14.6% for PPIs).

Pantoprazole: When dabigatran etexilate was coadministered with pantoprazole, a decrease in dabigatran area under